Granzyme B is a naturally occurring human protein used by our immune cells to kill target cells
It is a highly cytotoxic payload with a 3-prong killing mechanism that is irreversible, making it a very effective anti-cancer killing agent.
It is safer than other drug delivery therapies because there is no hepatic or renal toxicity or immunogenicity, no vascular leak syndrome and no impact by drug resistant genes MDR/MRP
Induction of Intense, Irreversible, Activation of 3 distinct cell death pathways
How do we deliver Granzyme B
Granzyme B (GrB) is fused to a molecule that targets tumors and internalizes GrB into the cancer cell.
This is the same mechanism of action as employed by the immune system and targeted immune cell therapy; however, accomplished in a simpler and safer manner.
The internalized Granzyme B is active in released and non-released forms.
The fusion protein manufacturing process is simplistic and, therefore, less costly and time-consuming as for approved immunotoxins
Targeted Granzyme B delivery using a fusion protein is more efficient than the natural Granzyme B pathway
